New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 31, 2012
08:26 EDTOMEROmeros shares oversold, secondary endpoint met, says Maxim
Maxim says that while OMS103HP missed its primary endpoint, the drug met its secondary endpoint of pain. The firm adds that pain is directly related to inflammation and the surgical process itself. Maxim finds Omeros shares oversold and said itís a buyer of the stock.
News For OMER From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 22, 2015
07:10 EDTOMEROmeros receives positive opinion from EMA's committee for Omidria
Omeros announced that the European Medicines Agency's Committee for Medicinal Products for Human Use has adopted a positive opinion for Omidria 1%/0.3%. Omidria is used during cataract surgery and other intraocular lens replacement procedures to maintain mydriasis, prevent miosis, and reduce postoperative eye pain. Cataract surgery and IOL replacement are among the most common surgical procedures worldwide, with approximately 3.9 million of them expected to be performed in Western Europe alone in 2015. Omidria was approved by the FDA in 2014 and last month was made broadly available nationwide for commercial use.
May 11, 2015
16:40 EDTOMEROmeros reports Q1 EPS (51c), consensus (63c)
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use